Earnings
Voyager Cuts Research Spending To $24.4 Million, Extends Funding Outlook Into 2028
The biotech expects Alzheimer’s imaging results in the fourth quarter and first gene-therapy dosing in the coming months, pending enrollment.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
Earnings
The biotech expects Alzheimer’s imaging results in the fourth quarter and first gene-therapy dosing in the coming months, pending enrollment.
SEC Filings
AYON and international generator sales lifted the quarter, while manufacturing customers bought less.
Earnings
Collection timing and higher interest payments hurt cash generation, while buybacks helped lift adjusted earnings per share.
Markets
The studio returned to an operating profit and reaffirmed its forecast for significant growth in adjusted operating earnings.
SEC Filings
Solitude offers access to better gas pricing, but Devon’s contractual exposure exceeds its quarter-end cash balance.
SEC Filings
The rare-disease drugmaker plans research staffing cuts exceeding 100 roles as its sickle cell application faces a longer FDA review.
Earnings
Management expects recruiting to help margins in 2027, but weaker residential orders are squeezing the fourth-quarter outlook.
SEC Filings
The company expects its cash to fund operations into 2028, with pivotal myasthenia gravis results expected in early 2027.
Earnings
Record orders support growth, but tariffs, aluminum costs and a stronger Colombian peso cut into quarterly earnings.
SEC Filings
The semiconductor supplier forecasts another increase in quarterly revenue, while its annual profit comparison includes a refinancing charge.
Earnings
The glasses seller kept its adjusted earnings outlook intact as Intelligent Eyewear launch spending pushed quarterly free cash flow below zero.
SEC Filings
Auryxia sales fell under pressure from generic competition, while inventory reductions limited Vafseo revenue.